TY - JOUR
T1 - Best practices for the management of thymic epithelial tumors:
T2 - A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)
AU - collaborators, TYME network
AU - Imbimbo, Martina
AU - Ottaviano, Margaret
AU - Vitali, Milena
AU - Fabbri, Alessandra
AU - Leuzzi, Giovanni
AU - Fiore, Michele
AU - Franceschini, Davide
AU - Pasello, Giulia
AU - Perrino, Matteo
AU - Schiavon, Marco
AU - Pruneri, Giancarlo
AU - Dei Tos, Angelo Paolo
AU - Sangalli, Claudia
AU - Garassino, Marina Chiara
AU - Berardi, Rossana
AU - Alessi, Alessandra
AU - Calareso, Giuseppina
AU - Petrini, Iacopo
AU - Scorsetti, Marta
AU - Scotti, Vieri
AU - Rosso, Lorenzo
AU - Rea, Federico
AU - Pastorino, Ugo
AU - Casali, Paolo Giovanni
AU - Ramella, Sara
AU - Ricardi, Umberto
AU - Abate-Daga, Laura
AU - Torri, Valter
AU - Trama, Annalisa
AU - Palmieri, Giovannella
AU - Marino, Mirella
AU - Zucali, Paolo Andrea
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is scheduled to replace the Masaoka-Koga system, may create further difficulties in TET management, that remains challenging. Several guidelines for treatment of TETs are available and provide recommendations based mainly on non randomized trials and retrospective or limited series. Often the lack of evidence leads to formulation of indications based on expert opinions. As for other rare cancers it is crucial to create networks to coordinate the work among centres involved in treatment of these diseases in order to offer the best diagnostic and therapeutic tools. For this purpose, in 2014 a network named TYME (ThYmic MalignanciEs), was founded in Italy with the aim of improving care and research in TETs. In September 2017 a panel of multidisciplinary experts from TYME network and from other Italian centres strongly involved in TET diagnosis and treatment convened a first Italian Expert meeting together with representatives of association for patients affected by rare thoracic cancers Tu.To.R, to explore how these tumors are managed in the different centres of Italy compared to ESMO guidelines. In this paper we summarize the issues discussed during that meeting and we propose recommandations based on Masaoka Koga and the new TNM staging system.
AB - Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is scheduled to replace the Masaoka-Koga system, may create further difficulties in TET management, that remains challenging. Several guidelines for treatment of TETs are available and provide recommendations based mainly on non randomized trials and retrospective or limited series. Often the lack of evidence leads to formulation of indications based on expert opinions. As for other rare cancers it is crucial to create networks to coordinate the work among centres involved in treatment of these diseases in order to offer the best diagnostic and therapeutic tools. For this purpose, in 2014 a network named TYME (ThYmic MalignanciEs), was founded in Italy with the aim of improving care and research in TETs. In September 2017 a panel of multidisciplinary experts from TYME network and from other Italian centres strongly involved in TET diagnosis and treatment convened a first Italian Expert meeting together with representatives of association for patients affected by rare thoracic cancers Tu.To.R, to explore how these tumors are managed in the different centres of Italy compared to ESMO guidelines. In this paper we summarize the issues discussed during that meeting and we propose recommandations based on Masaoka Koga and the new TNM staging system.
KW - Expert meeting
KW - Masaoka-Koga
KW - Thymic carcinoma
KW - Thymic epithelial tumors
KW - Thymoma
KW - TNM
U2 - 10.1016/j.ctrv.2018.10.001
DO - 10.1016/j.ctrv.2018.10.001
M3 - Article
VL - 71
SP - 76
EP - 87
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
SN - 0305-7372
ER -